Carmen Mak
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Hepatitis C virus research, HIV Research and Treatment, Cancer-related Molecular Pathways, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C(2002)977 cited
- → Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis(2018)651 cited
- → Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials(2016)311 cited
- → Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial(2013)180 cited
- → Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment‐Experienced Subjects: 48‐Week Results of the VICTOR‐E1 Phase 2 Trial(2010)44 cited
- → Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials(2012)38 cited
- → Impact of Different Regulatory Requirements for Trial Endpoints in Multiregional Clinical Trials(2011)13 cited
- → Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events(2021)12 cited
- → Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.(2016)8 cited
- → Points to Consider in Defining Region for a Multiregional Clinical Trial: Defining Region Work Stream in PhRMA MRCT Key Issue Team(2011)6 cited